October 16, 2022 from 12:00 pm – 1:00 pm CDT
Supported By: Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson, Bayer, Janssen Therapeutics, division of Janssen Products, LP, Merck & Co. Inc., and United Therapeutics Corporation.
Pulmonary arterial hypertension (PAH) is a chronic, progressive form of pulmonary hypertension (PH) that ultimately leads to right-sided heart failure and premature death. Though management has greatly advanced over the past 2 decades, it varies according to etiology, functional class, hemodynamic parameters, and other clinical factors. Evidence-based strategies for combination therapy and timely escalation of treatment that is based on risk stratification and clinical response have modernized the treatment of PAH.
In this interactive CME-certified symposium, top experts will focus on the latest guideline updates and strategies for improving early diagnosis and treatment, with the goal of delaying disease progression and improving outcomes.
Josanna Rodriguez-Lopez, MD
Massachusetts General Hospital
Jean M. Elwing, MD
University of Cincinnati
Professor of Clinical Internal Medicine
Martha Kingman, FNP-C, DNP
University of Texas Southwestern Medical Center
Pulmonary Hypertension Clinic
Family Nurse Practitioner
Vallerie V. McLaughlin, MD
University of Michigan
Pulmonary Hypertension Program
Ann Arbor, MI